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Immunotherapy is the field of immunology that aims to identify treatments for 
diseases through induction, enhancement or suppression of an immune response. 
Immunotherapies designed to instigate or enhance an immune response are considered 
“activating immunotherapies” while those designed to repress an immune response are 
“suppressive immunotherapies.” This perspective will focus on two areas of immuno-
therapy, activating immunotherapies for cancer and suppressive immunotherapies for 
autoimmunity both of which have seen a resurgence in interest in recent years and 
are likely to transform the treatment of many human diseases in the next 20  years. 
Effective immunotherapies for cancer, where the aim is to activate tumor-specific 
immune responses, will be totally different from those designed to suppress the immune 
response to self-antigens in autoimmune disease. Furthermore, the reader will appreci-
ate that the degree to which side effects of immunotherapies are acceptable will differ 
drastically between life-threatening cancers and chronic, debilitating but not necessarily 
life-threatening autoimmune conditions.
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tHe GLOBAL HeALtH BUrDeN
Improvements in sanitation and effective vaccination are gradually reducing the impact of infec-
tious diseases across the world. The World Health Organisation (WHO) predicts a continuing 
decline in global mortality resulting from respiratory, perinatal, and other infections, excluding 
HIV/AIDS. While global mortality due to AIDS has declined rapidly, this rate is not predicted 
to change dramatically over the coming 20  years (1). By contrast, global mortality due to car-
diovascular disease, cancer, non-infectious respiratory disease, and other inflammatory diseases 
will increase with cardiovascular disease predicted to be the greatest killer followed by malignant 
neoplasms and chronic obstructive pulmonary disorder. There is a disturbing increase in the 
incidence and prevalence of immune-mediated inflammatory diseases (IMIDs), including autoim-
mune and auto-inflammatory diseases. Among these, neurological conditions, such as multiple 
sclerosis (MS) and myasthenia gravis, are increasing at a rate of 3.7% per year while rates for 
gastrointestinal, endocrine, and rheumatic diseases are increasing by at least 6% per year (2). 
Type 1 diabetes is increasing rapidly across Europe and North America and, most disturbingly, 
the greatest rate of increase is in the 0- to 4-year age group (3). Similar rises in incidence rate are 
seen for a range of other autoimmune conditions. Crohn’s disease and ulcerative colitis, examples 
of auto-inflammatory conditions, are increasing at a similar rate across the world, reflecting their 
emergence as global diseases (4).
FiGUre 1 | Immune-mediated inflammatory diseases. This figure is based on “A proposed classification of the immunological diseases” by McGonagle and 
McDermott (5). The figure distinguishes the etiological basis of auto-inflammatory and autoimmune diseases and more clearly defines the definition of these diseases 
according to their monogenic or polygenic basis. The spectrum of diseases proposed are more associated with either innate (auto-inflammatory) or adaptive 
(autoimmune) immune responses and range from monogenic auto-inflammatory to monogenic autoimmune diseases. This classification not only helps us 
understand the genetic and immunological basis of the disease but also predicts more effective means of immunotherapy.
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iMMUNe-MeDiAteD iNFLAMMAtOrY 
DiseAses
The increasing prevalence of IMIDs demands a more precise 
classification and better fundamental understanding of the 
pathology underlying these diseases. This will lead to improved 
diagnosis through use of selective biomarkers, earlier detection 
and intervention thereby avoiding complications, identifica-
tion of high-risk populations through better understanding of 
genetic and environmental influences enabling avoidance of 
contributory triggers or prevention through immunotherapy. 
McGonagle and McDermott proposed a classification of IMIDs 
based on the genetic factors involved in their etiology (5). They 
defined monogenic auto-inflammatory diseases, such as Blau 
syndrome, familial Mediterranean fever, and tumor necrosis 
factor receptor-associated periodic syndrome, as being one end 
of a spectrum of inflammatory diseases with monogenic auto-
immune diseases, such as autoimmune lymphoproliferative 
syndrome, immune dysregulation polyendocrinopathy enter-
opathy X-linked syndrome, autoimmune polyendocrinopathy 
candidiasis ectodermal dystrophy, and certain complement 
deficiencies as the other end of the spectrum (Figure 1). The 
vast majority of both auto-inflammatory and autoimmune dis-
eases, such as type 1 diabetes (6), are polygenic and, therefore, 
fall in between the two ends of the spectrum. Generally speak-
ing auto-inflammatory diseases are associated with mutations 
influencing innate immunity, including the inflammasome 
genes, and are not associated with autoantibodies, autoreactive 
T cells or have MHC-disease associations. On the other hand, 
genetic polymorphisms associated with autoimmune diseases 
are found in genes regulating the adaptive immune system and 
together these permit the generation and subsequent lack of 
control of autoreactive T cells leading to production of autoan-
tibodies. Strikingly, most classical autoimmune diseases have a 
strong association with genes in the MHC class II and are more 
common in women than men (7). Of the 5–10% of people in 
Western countries suffering from autoimmune diseases approx-
imately 80% are women. This may be because X-chromosome 
inactivation or reactivation influences self-tolerance or the 
possibility that X-chromosome encoded miRNAs may influ-
ence susceptibility to autoimmune diseases. Furthermore, it is 
clear that both X-linked genes and the sex hormones produced 
influence innate and adaptive immunity, inflammation, and 
autoimmunity (7).
iMMUNOtHerAPY OF AUtOiMMUNe 
DiseAses
The Holy Grail for treatment of autoimmune diseases is to dis-
cover a means of selectively suppressing the specific autoimmune 
disease while leaving the rest of the immune system functionally 
active for control of infectious diseases and cancers. The aim is 
to develop treatments with increasing specificity for disease in 
order to decrease the risk of potential side effects. The ultimate 
aim is to provide a cure; however, the likelihood of success for 
this aim will depend on the particular autoimmune disease and 
associated pathology. For example, it may be sufficient to deplete 
autoreactive cells to correct the immune imbalance and reset 
homeostatic control of autoreactivity. In other cases, however, 
it may be necessary to continue treatment to arrest disease 
progression.
Currently, control of autoimmune diseases depends on the 
use of non-specific immunosuppressive drugs with associated 
side effects. Taking multiple sclerosis (MS) as an example, 
there are a variety of treatments that are being developed that 
aim to increase specificity for disease. Alemtuzumab is an 
antibody specific for CD52 that deletes all leukocytes and has 
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a dramatic effect on the inflammation in and progression of 
MS. A median seven-year follow-up of relapsing–remitting MS 
patients treated with Alemtuzumab revealed that up to 70% 
of trial participants had an improved or unchanged disability 
compared to baseline. However, treatment was associated with 
secondary autoimmunity in approximately 48% of the treated 
individuals, with Graves’ disease being the most common 
complication (8).
Multiple sclerosis is considered to be a T-cell mediated 
disease; however, depletion of CD4 T  cells alone was not an 
effective treatment (9). MS is characterized by the presence of 
oligoclonal bands of immunoglobulins in cerebrospinal fluid 
(10); however, it has been difficult to associate these antibod-
ies with a clear target for autoimmune pathology. Nevertheless 
targeting CD20 on B cells is proving an effective means of con-
trolling relapsing–remitting MS and even reducing disability in 
primary progressive disease (11). CD20 is expressed on pre-B, 
naïve, and memory B  cells but not plasma cells. It is thought 
that depletion of these cells by rituximab or ocrelizumab will 
affect not only production of potentially pathogenic antibodies 
but also cytokine secretion by B cells and most likely their ability 
to present antigen to T cells (12, 13). Side effects due to B cell 
depletion appear limited to a higher than normal risk of herpes 
reactivation and breast cancer (11).
Drugs designed to reduce lymphocyte migration into the CNS 
have shown promising results. For example, fingolimod acts as 
a Sphingosine 1 phosphate (S1P) receptor agonist that results 
in S1P receptor downregulation thereby preventing lymphocyte 
migration from lymph nodes (14). This drug has a temporary 
effect on heart rate but otherwise has remarkably few side effects. 
A more targeted drug, preventing T cell migration into the CNS, 
is natalizumab. This drug targets the integrin VLA-4 required for 
lymphocytes to cross the blood brain barrier and reduces annual 
relapse rates and disability progression. However, there is a 1/300 
chance of developing progressive multifocal leukoencephalopa-
thy (PML) as a result of treatment (15). PML is caused by the 
human polyoma JC virus that infects and kills oligodendrocytes 
causing devastating damage when immune surveillance of the 
CNS is compromised.
It is difficult to see how non-specific manipulation of the 
immune response in autoimmune diseases such as MS will 
ever be completely safe or free of side effects. One increasingly 
promising approach is the use of low-dose interleukin 2 for 
treatment of autoimmune diseases (16). This relies on the fact 
that effector T  cells respond weakly to low-dose IL-2 in  vivo 
whereas Foxp3+ Treg cells, which express the high-affinity IL-2 
receptor (CD25), proliferate following low-dose IL-2 treatment 
in vivo (17). Low-dose IL-2 treatment is well tolerated; however, 
it is possible that non-specific expansion of the Foxp3+ Treg 
population may influence susceptibility to infections and cancer 
in some individuals.
Many of the autoantigens associated with autoimmune dis-
eases, such as MS, are known (18). In light of this, a number of 
groups have begun developing approaches designed to selectively 
target antigen-specific lymphocytes associated with autoimmune 
diseases. These range from injection of T-cell epitopes derived 
from self-antigens (19–22) through administration of tolerogenic 
dendritic cells carrying autoantigen peptides (23), the design of 
nanoparticles combined with peptide alone (24) or peptide and 
immunosuppressive drug (25) to the sophisticated construction 
of nanoparticles coated with complexes of MHC class II molecules 
and antigenic peptides (26, 27). Currently, the mechanisms by 
which these antigen-specific approaches protect against and treat 
autoimmune diseases are not clear. Work in preclinical models of 
autoimmune disease show that they function by either deleting 
autoreactive T cells, inducing anergy, or generating cells with a 
regulatory phenotype. Most importantly, results of clinical trials 
have not revealed significant side effects associated with antigen-
specific immunotherapies.
In the next 20 years, we will discover that different regulatory 
T cell populations protect against different immune pathologies, 
including autoimmune diseases. Accordingly, we will design 
antigen-specific approaches optimized for induction of Foxp3+, 
IL-10-secreting Tr1-like, or CD8+ Treg all of which have been 
associated with protection from disease through antigen-specific 
immunotherapy. We will know how to administer antigens to 
selectively induce the relevant Treg population and will have 
tested the most effective delivery approach. Furthermore, we will 
have discovered drugs to co-administer with antigens in order to 
promote specific subsets of regulatory cells; for example, GSK-3 
have been shown to promote IL-10 secreting Tr1-like cells (28) 
while PI3 Kinase inhibitors selectively support Foxp3+ Treg cells 
(29). Most importantly, it will be essential to identify drugs that 
make it possible for regulatory cells to function in an inflamma-
tory environment (30–32).
iMMUNOtHerAPY OF cANcer
Cytotoxic T  cells are potent killers of cancer cells. However, 
both CD4 and CD8 tumor-infiltrating lymphocytes (TILs) tend 
to be suppressed and, hence, unable to control tumor growth. 
There are various mechanisms leading to suppression of TILs 
including the presence of Treg cells (33, 34) and the secretion 
of inhibitory mediators, such as adenosine, prostaglandins, and 
arginase (35–38). A universal feature of TILs is the upregulation 
of inhibitory receptors on those cells that are unable to control 
the cancer (39). Molecules currently under investigation include 
CTLA-4, PD-1, LAG-3, TIGIT, and Tim-3. The outcome of 
clinical trials reveals that antibodies to PD-1 and CTLA-4 are 
extremely powerful in reversing the suppression of TILs. Their use 
has shown great promise in different cancer types, prominently 
melanoma and small-cell lung carcinoma (40). However, the use 
of such “checkpoint inhibitors” does not work in all patients and 
we currently do not understand why. Furthermore, the use of 
checkpoint inhibitors, such as the combination of anti-PD-1 and 
anti-CTLA-4, causes severe toxicity in the majority of patients 
treated. Toxicity depends on the individual and ranges from 
inflammation of the GI tract, the most common complication, to 
autoimmune phenomena affecting the thyroid, skin, liver, joints, 
pancreas, and brain, i.e., common targets for organ-specific 
autoimmune diseases. At this time, we do not understand why 
treatment with the same combination of antibodies induces 
discrete autoimmune phenomena in different individuals; 
presumably, this reflects the presence of selective groups of 
FiGUre 2 | Immunotherapy of cancer. This figure depicts the effect of immunotherapy with checkpoint inhibitors on the immune system. (A) It reflects the steady 
state in which both tumor-antigen reactive and self-antigen reactive T cells remain quiescent, i.e., in a state of tolerance. (B) When checkpoint inhibitors such as 
anti-PD-1 and anti-CTLA-4 are administered, both tumor-specific and autoreactive T cells break tolerance, respond to their antigens, clear the tumor, but allow 
expansion of autoreactive T cells resulting in autoimmune disease. (c) It reflects the situation where either the type of inhibitory receptor targeted by checkpoint 
inhibitor is changed or the amount of checkpoint inhibitor is reduced to a level that does not trigger autoreactive T cells. It is suggested, however, that 
coadministration of a selective cancer vaccine will lead to expansion of tumor-specific T cells and hence tumor clearance.
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pre-disposing genes in these individuals. Much current research 
involves investigation of altered dosing regimens or combinations 
of checkpoint inhibitors in order to reduce the level of toxicity. 
Injection of checkpoint inhibitors directly into metastatic tumor 
sites could enhance their efficacy with less associated toxicity as 
shown for Treg depleting antibodies (41). However, breaking 
the tolerance of TILs may never be possible without causing 
some degree of induced self-reactivity unless there is a means 
of selectively activating tumor-specific cells while leaving other 
self-reactive cells dormant.
The future of cancer immunotherapy lies in the combination 
of selective cancer vaccines and checkpoint inhibitors or some 
other means of relieving immune suppression associated with 
the tumor. As shown in Figure  2, it is possible to lower the 
threshold for effective antitumor immunity by blocking inhibi-
tory receptors such as PD-1 and CTLA-4. However, the use of 
checkpoint inhibitors alone (Figure  2B) will never selectively 
activate tumor-specific cells without coincidentally causing 
activation of self-reactive cells and, hence, causing some form 
of auto-inflammatory or autoimmune condition. Currently, we 
understand very little about how most of the inhibitor receptors 
targeted by checkpoint inhibitors actually function (42). These 
molecules downregulate cell signaling at the immune synapse; 
however, the mechanisms involved are largely unknown. Detailed 
knowledge of this would reveal common signaling and regulatory 
pathways that could provide more controlled targets for pharma-
ceutical intervention. Ultimately, it should be possible to reduce 
the level of or change the combination of checkpoint inhibitors, 
such that self-reactive cells are no longer activated. We then need 
a means of selectively immunizing for an antitumor response 
using a cancer vaccine.
Importantly, we are entering a revolutionary era for research 
into the neoantigens associated with tumors and the application 
of this knowledge in vaccine development. For example, the 
use of massively parallel sequencing for detection of mutations 
within tumors combined with machine learning approaches, to 
predict which of those mutated peptides bind with high affinity to 
HLA molecules, has allowed development of immunogenic vac-
cines targeting predicted neoantigens. A recent study described 
the application of this approach in melanoma whereby four 
of six vaccinated patients had no recurrence 2  years after vac-
cination while two with recurrent disease experienced complete 
tumor regression following treatment with anti-PD-1 (43). This 
outstanding achievement, combining molecular analysis and 
computer prediction, holds great promise for the future of cancer 
vaccination and shows the power of combination immuno-
therapies. The same combination approach could be applied to 
the tumor microenvironment whereby inhibition of suppressive 
molecules, such as adenosine, prostaglandin, or arginase, could 
be combined with a vaccine to boost the anti-cancer approach. 
The next 20 years will see a stream of breakthroughs in which 
immunotherapeutic approaches are combined to selectively 
target tumors while avoiding unnecessary toxicities.
cONcLUsiON
The immune system has evolved to protect us from infection. 
The human immune system is immensely complex and the 
drawback of developing an immune system that may recognize 
and respond to all infections is the potential for hypersensitivity 
reactions. These manifest as allergic responses to environmental 
agents and autoimmune responses to self-antigens. Equally, the 
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immune system has developed sophisticated regulatory mecha-
nisms to protect against rejection of the human allograft during 
pregnancy and reduce the risk of autoimmune diseases. These 
immune regulatory mechanisms serve as barriers to effective 
cancer immunity: the challenge to cancer control and eradica-
tion is how to have one without the other, i.e., how to promote 
effective cancer immunity without the toxic side effects of auto-
immune diseases. Recent breakthroughs in the use of checkpoint 
inhibition, when combined with cancer vaccination, will make 
this feasible: the key factor is to target the relevant cancer antigen. 
For autoimmune diseases, we have depended on non-specific 
immunosuppressive drugs for far too long. We have failed to 
learn from the allergy field where effective immunotherapy is 
achieved by targeted desensitization using allergy associated 
antigens. The antigen-specific immunotherapies referred to in 
this perspective article herald a new era of immunotherapy for 
autoimmune diseases where again the key factor is to target the 
relevant antigen, in this case the self-antigen.
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